PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge
Open Access
- 11 April 2018
- journal article
- research article
- Published by Springer Nature in Biomarker Research
- Vol. 6 (1) , 1-8
Abstract
Inhaled allergen challenges are often used to evaluate novel asthma treatments in early phase clinical trials. Current novel therapeutic targets in asthma include phosphoinositide 3-kinases (PI3K) delta and gamma, p38 mitogen-activated protein kinase (p38) and Janus kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling pathways. The activation of these pathways following allergen exposure in atopic asthma patients it is not known. We collected bronchial biopsies from 11 atopic asthma patients at baseline and after allergen challenge to investigate biomarkers of PI3K, p38 MAPK and JAK/STAT activation by immunohistochemistry. Cell counts and levels of eosinophil cationic protein and interleukin-5 were also assessed in sputum and bronchoalvelar lavage. Biopsies collected post-allergen had an increased percentage of epithelial cells expressing phospho-p38 (17.5 vs 25.6%, p = 0.04), and increased numbers of sub-epithelial cells expressing phospho-STAT5 (122.2 vs 540.6 cells/mm2, p = 0.01) and the PI3K marker phospho-ribosomal protein S6 (180.7 vs 777.3 cells/mm2, p = 0.005). Type 2 inflammation was increased in the airways post allergen, with elevated levels of eosinophils, interleukin-5 and eosinophil cationic protein. Future clinical trials of novel kinase inhibitors could use the allergen challenge model in proof of concept studies, while employing these biomarkers to investigate pharmacological inhibition in the lungs.Keywords
Funding Information
- North West Lung Research Charity, Manchester, UK
- Almirall, S.A, Barcelona, Spain
This publication has 32 references indexed in Scilit:
- Mitogen-activated protein kinases as therapeutic targets for asthmaPharmacology & Therapeutics, 2017
- An investigation of the anti-inflammatory effects and a potential biomarker of PI3Kδ inhibition in COPD T cellsClinical and Experimental Pharmacology and Physiology, 2017
- A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patientsPulmonary Pharmacology & Therapeutics, 2016
- Achieving asthma control with ICS/LABA: A review of strategies for asthma management and preventionRespiratory Medicine, 2016
- Aeroallergen Der p 2 induces apoptosis of bronchial epithelial BEAS-2B cells via activation of both intrinsic and extrinsic pathwayCell & Bioscience, 2015
- Ribosomal Protein S6 Phosphorylation2015
- Asthma Phenotypes: Nonallergic (Intrinsic) AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthmaNature Medicine, 2013
- IFN‐γ synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid‐resistant STAT1 activationBritish Journal of Pharmacology, 2012
- Intrinsic Phenotypic Differences of Asthmatic Epithelium and Its Inflammatory Responses to Respiratory Syncytial Virus and Air PollutionAmerican Journal of Respiratory Cell and Molecular Biology, 2011